Changing frontline AML treatment patterns from 2013 to 2022.

Area of Science:

• Hematology
• Oncology
• Real-world evidence studies

Background:

• Acute myeloid leukemia (AML) treatment has evolved, necessitating analysis of contemporary treatment patterns.
• Understanding shifts in therapy for elderly AML patients is crucial for optimizing care.

Purpose of the Study:

• To compare treatment patterns for newly diagnosed AML patients between 2013-2016 and 2021-2022.
• To evaluate changes in non-intensive therapy (NIT) utilization and outcomes in older AML patients.

Main Methods:

• Retrospective analysis of real-world treatment data for AML patients.
• Comparison of treatment modalities (intensive, non-intensive, none) and outcomes (complete response, overall survival) between two distinct time periods.

Main Results:

• A significant increase in NIT use was observed in patients aged 70+ (65% in 2021-22 vs. 44% in 2013-16).
• Complete response rates (69% vs. 24%) and overall survival (11.5 vs. 7.8 months) improved significantly for NIT patients.
• Treatment patterns for patients under 70 remained unchanged; older rural patients were more likely to decline therapy.

Conclusions:

• The rise in NIT for elderly AML patients correlates with improved outcomes, likely due to more effective therapeutic options.
• Despite advancements, overall survival with non-intensive therapy for AML remains suboptimal, highlighting the need for continued research and development.